The Swiss multinational CDMO, which provides contract development and manufacturing services to the pharmaceutical and biotech industries, has signed a 15-year lease of the 42,000 sq ft Gonville building, an impressive two-winged building, linked by a central reception block. Situated at the heart of the Park and within easy reach of The Nucleus central facilities building, the Gonville Building is ideally positioned to ensure Lonza staff are able to take full advantage of all that Chesterford Research Park has to offer.
The move to Chesterford will enable Lonza to expand its capabilities to support risk assessment and development of early stage biotherapeutics and vaccines. With the market witnessing a growing pipeline of increasingly complex biologic medicines, Lonza is driving new solutions to enable its customers to move quickly and effectively towards treating patients in clinical trials.
Rob Sadler, Head of Savills Cambridge Office commented: “This is a significant move for Lonza as a major customer within the cluster. The fact that we have been able to pre-let the Gonville Building is testament not only to the strength of the market, but also to the Park itself. We are seeing significant interest in Chesterford from a number of sources, as evidenced by this and other recent deals. The Newnham Building for example, which is currently being completely refurbished has garnered significant interest – so much so that one suite is now confirmed as pre-let to Isomerase, and of the remaining three two are currently under offer, despite the fact that the building is not due for completion until 2020. Given the intensity of interest in Chesterford Research Park and looking to the future, discussions are already underway to scope Chesterford’s next phase of speculative development; it’s an incredibly exciting time for the Park.”
Yvette Stallwood, Head of Applied Protein Services (APS), Lonza Pharma & Biotech added: “Relocating the Cambridge site operations from Granta Park to Chesterford Research Park allows us to continue to expand our operations and services to support our customers. Increased capacity in the Gonville Building will provide laboratory and office space to further advance risk assessment and development of early-stage biotherapeutics and vaccines. The refurbishment programme is already underway and we plan to relocate the Cambridge operations in Q1 2020.”